As part of the Framework for Modeling HPV Prevention (HPV-FRAME) consortium, general principles for models of universal HPV vaccination in females and/or males will be presented. This talk will present the additional draft HPV-FRAME reporting requirements for parameters for comparative evaluations of different vaccine types and/or reduced dose schedules.
We identified distinct parameters that are critical to specify in comparative model-based analyses of alternative vaccines including the differential levels of vaccine cross-protection (i.e., level and duration of protection against specific types), cost (per dose) and total cost per vaccinated girl for each vaccine, assumptions regarding type replacement in the model, and any assumptions regarding differential uptake and/or availability of the vaccines. F9r alternative dosing schedules, important specifications include efficacy and duration of protection against specific types, assumed schedule between more than 1dose, target age groups for reduced dose schedule, cost (per dose) and total cost per vaccinated girl for 1-dose or 2-dose schedules, assumptions regarding cross-protection for less than three doses, and assumptions regarding differential uptake and scale-up for policies involving different dosage schedules.
Clear and consistent reporting of inputs and assumptions in evaluations comparing different HPV vaccines and alternate vaccine dosing schedules are critical for interpreting results, assessing quality of analyses, and facilitating comparisons across studies.